Genome & Company
B-8F Silicon Park, 35 Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13486
Consent to collection and use of personal information (Required)
Genome & Company (the ”Company”) regards the protection of personal information of our users very important, and complies with relevant laws, including the Personal Information Protection Act and the Act on Expansion of Dissemination and Promotion of Utilization of Information System. The Company hereby informs the purpose and method of using the personal information provided by our users through the Company’s website, and what measures are taken to protect the personal information. If the Company revises any of this Private Policy, it will be notified through the notices on the Company’s website (or individually notified).
The Company collects the following personal information to operate its Contact Service via the Company’s website (whereby the users can make general inquires, inquiry for business development, IR inquiry, media inquiry, etc.).
- Essential Information: name, e-mail address, phone number, organization, content of inquiry
- Collection method: The Company collects the personal information through the inquiries submitted via the Contact Bulletin Board on the Company’s website.
You have the right to refuse the ‘collection of essential information’ as well as the ‘collection of optional information’. If you refuse the collection of essential information, however, you may be restricted for using the Contact Service.
The following information may be automatically generated and collected in the process of using the website.
- IP Address, cookie, date and time of visit, records of service use
The Company uses the collected personal information for the following purposes.
- Personal verification, personal identification, delivery of inquiries and notification of results (answers and responses), etc. related to the use of Contact Service
In principle, the collected personal information is destroyed without any delay after achieving the purpose of collecting and using personal information. However, the Company may keep users’ information for a certain period of time as required by relevant laws.
- Retained information: personal information submitted with the inquiry, content of the inquiry, and ensuing responses
- Relevant Law: Act on the Consumer Protection in Electronic Commerce, etc.
- Retention Period: three years (records related to resolution of consumer complaints or disputes)
In principle, the information is destroyed without any delay after achieving the purpose of collecting and using personal information. The procedure and method of destruction are as follows.
The personal information submitted is transferred to a separate database (in case of paper, separate cabinet) after achieving the purpose and kept for a certain period of time according to the internal policy and other relevant laws, before it is destroyed. The personal information transferred to separate database shall not be used any other purposes other than for keeping in accordance with laws.
2) Destruction Method
Personal information saved in the form of electronic file shall be deleted by using technical method that cannot reproduce the records. Personal information printed in the paper shall be destroyed by shredding with a shredder or incinerating it.
In case users request the correction of any errors in personal information, we shall not use or provide the personal information until such correction is made. In addition, in case incorrect personal information is already provided to a third party, we will notify the third party the result of correction without delay.
The Company processes and destroys personal information at the request of users or their legal representatives in accordance with Section ‘3. Processing of Personal Information and Retention Period’ and Section ‘4. Destruction of Personal Information’, and such information shall not be opened or used for any other purposes.
The Company designates data protection officer and manager for managing personal information as follows to protect users’ personal information related to inquiries.
Data Protection Officer
Name: Seo Yeong-jin
Department: Business management
Data Protection Manager
Name: Seol Su-gi
Department: PR team
Position: Team Lead
You can submit to the personnel above any inquiries related to your personal information submitted to the Company while using our web service. The Company will quickly provide sufficient responses to your inquiries.
Please contact the below agencies if you need report or counseling for any infringement of personal data privacy.
- Personal Information Infringement Report Center (privacy.kisa.or.kr / 118 without area code)
- Personal Information Dispute Mediation Committee (kopico.go.kr / 1833-6972)
- Cyber Investigation Department, Supreme Prosecutor’s Office (www.spo.go.kr / 1301 without area code)
- Cyber Bureau of the National Police Agency (http://cyberbureau.police.go.kr / 182 without area code)
Genome & Company has established a new drug development platform, GNOCLE™ and effectively conduct research and development in innovative microbiome and novel target based therapeutics. A such unique “Bed-to-Bench” approach using real-world clinical data collected from research institutions and hospitals significantly enhances the success probability of new drug development.
*Click the pipeline name in the table to find more details
|Program||Indication||Discovery||Preclinical||Phase I||Phase II||Our partners|
Phase 2 clinical study will be conducted in the second half of 2021
||cancer associated rash|
* Non-small cell lung carcinoma, head and neck carcinoma, urothelial cancer, etc.
*Click the pipeline name in the table to find more details
|Program||Target validation &
|Lead optimization &
(CMC, Pharmacology, Toxicology)
New biologics for cancer treatment
|GENA-111, etc. (ADC)|
'GEN-001', a leading pipeline of Genome & Company is a candidate for immuno-oncology microbiome therapeutic.
'GEN-001' is being developed as an orally administered microbiome therapeutic with Lactococcus lactis (L. lactis), single live bacterial strain that is isolated from a healthy human.
In the pre-clinical setting, 'GEN-001' has proven anti-cancer efficacy through the activation of immune activity of cancer patients as a monotherapy as well as in combination with the existing immunotherapy/immune checkpoint inhibitors.
Currently, clinical studies (Phase I/Ib) targeting multiple solid cancer patients are being conducted in the US and Republic of Korea, and clinical study) targeting gastric cancer patients will be conducted in Korea.
*Find more details at website.
‘SB-121’ is a clinical-stage pipeline under development by Scioto Biosciences, a US biotech acquired by Genome & Company in August 2020.
‘SB-121’ is developed by using Lactobacillus.reuteri (L.reuteri) strain derived from breast milk of a healthy mother with a proprietary drug formulation platform technology (ABT, Activated Bacterial Therapeutics) owned by Scioto Biosciences. Lactobacillus.reuteri strain has been confirmed to activate the secretion of oxytocin that affects to relieving autism through vagus nerves, confirmed by global neurological researchers.
‘SB-121’ is being developed for treatment of gut-brain axis related disorders, such as autistic spectrum disorders(ASD) and gut injury related diseases, namely necrotizing enterocolitis (NEC) and clostridium difficile infection(CDI). At pre-clinical setting, ‘SB-121’ has been confirmed to relieve gut injuries and activate the secretion of oxytocin.
‘SB-121’ has been cleared for investigational new drug(IND) of phase 1 clinical study targeting autism patients, and the study is ongoing in the US with the study read-out expected at the end of 2021/early 2022. Subsequently, a clinical study targeting necrotizing enterocolitis patients is being planned for 2022.
*Find more details at Scioto Biosciences website.
‘GEN-004’ is a candidate for microbiome therapeutic that has shown an in-vivo efficacy of increasing implantation of embryo.
‘GEN-004’ is being developed as an ovule formulation of live biotherapeutic products(LBP) single bacterial strain that is isolated from healthy human.
‘GEN-004’ inhibits immune responses that hinder embryo implantation and has antibacterial effects against harmful bacteria that cause vaginitis. The efficacy for increasing the embryo implantation rate with ‘GEN-004’ has been confirmed in in-vivo infertility model with induction of inflammation. 'GEN-004' is currently in pre-clinical stage.
'GEN-501' is a candidate for microbiome therapeutic that is under development by using Cutibacterium avidum (C.avidum) single strain that is isolated from the skin of healthy human.
‘GEN-501’ is being developed in the formulation for local application to the skin such as ointment. 'GEN-501' selectively inhibits Staphylococcus aureus (S.aureus) which is known to be the main cause of atopic dermatitis and cancer associated rash. 'GEN-501' is currently in preclinical study and is expected to enter phase 1 clinical study in 2022. 'GEN-501' is also expected to expand the target indications to other skin diseases occurred by the abundance of 'S. aureus' based on the progress of the clinical development.
Genome & Company specializes in discovery and validation of novel targets for anti-cancer applications.
Based on the validated novel target, Genome & Company conducts research and development of antibodies in immuno-oncology. Novel targets identified by Genome & Company was found to be strongly inhibiting immune cells (T cells) than PD-L1, the best known immune checkpoint.
Development of antibodies for a such novel targets is expected to enhance the activation of immune cells (T cell) than existing immunotherapy. Genome & Company aims to provide new treatment to patients who are non-responsive or resistance to the existing immunotherapy.
‘GENA-104’, a “first-in-class” immune checkpoint inhibitor, inhibits novel target (CNTN4) that suppresses T cell responses on tumor cells. Pre-clinical outcome of ‘GENA-104’ for its anti-cancer effects and its mechanism of action have been presented at American Association of Cancer Research (AACR) in 2021.
The final candidate for clinical development has been selected, and IND enabling study is currently ongoing.
Research and development for new drug by Genome & Company is not only limited to antibody for novel immuno-oncology target, but also other innovative anti-cancer therapeutics in new modalities based on the novel targets discovered through GNOCLE™, our proprietary drug development platform.
Genome & Company has entered research collaboration with Debiopharm, a global biopharmaceutical company for oncology therapeutics in February 2021. Genome & Company and Debiopharm are currently discovering therapeutic candidates for ADC by combining novel target antibodies developed by Genome & Company and various antibody-drug conjugate(ADC) technologies owned by Debiopharm.
Based on the joint R&D efforts, the partnership is expected to expand to global clinical development and commercialization of a novel ADC drug candidate.
*Find more details at Debiopharm website.